Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113347 · ClinicalTrials.gov registry record · Phase 1
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00113347: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00113347 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00113347, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
Interventions
- DRUG Docetaxel
- RADIATION Radiation Therapy
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113347
The ClinicalTrials.gov registry entry for NCT00113347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00113347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113347 about?
NCT00113347 is a clinical study titled "Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)". The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
What is the current status of trial NCT00113347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00113347?
The interventions under investigation include: Docetaxel (DRUG), Radiation Therapy (RADIATION), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00113347?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.